ARQT Arcutis Biotherapeutics Inc

Wall Street Zen has downgraded Arcutis Biotherapeutics (NASDAQ:ARQT) from a "strong-buy" to a "buy" rating, though the consensus analyst rating remains a "Moderate Buy" with an average price target of $29.00. Despite beating revenue and EPS estimates in its latest quarter, the company remains unprofitable. Insider activity shows sales totaling approximately $8.64 million over the last quarter, with insiders still owning 9.4% of the company's stock.

Perpetual Ltd significantly increased its holdings in Arcutis Biotherapeutics, Inc. ($ARQT) during Q3, adding nearly 2 million shares to own over 2 million shares valued at $38.16 million. Despite recent insider selling, analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $29.00. Arcutis also surpassed revenue and EPS expectations in its latest quarterly earnings report.

The volatile biotech industry has performed strongly in 2025, driven by new drug approvals, pipeline progress, and a surge in M&A activities, particularly with the rise of AI-driven drug discovery. Biotech companies like Arcutis Biotherapeutics, Amicus Therapeutics, and ANI Pharmaceuticals are highlighted as poised to outperform the sector due to their innovative pipelines and successful commercialization strategies. The industry, despite its inherent risks, continues to attract investor interest due to the continuous need for advanced medical treatments and breakthrough technologies.

Squarepoint Ops LLC significantly increased its stake in Arcutis Biotherapeutics (NASDAQ:ARQT) by 169.2% in the second quarter, bringing its total holdings to 167,814 shares valued at $2.35 million. This coincides with recent insider selling activity, with executives offloading shares worth millions, though insiders still collectively own a substantial portion of the company. Arcutis Biotherapeutics recently surpassed quarterly earnings and revenue expectations, and analysts generally maintain a "Moderate Buy" rating with a consensus price target of $29.

The biotech industry has shown strong performance in 2025 due to new drug approvals, pipeline progress, and increased M&A activity, driven by AI-driven drug discovery. Companies like Arcutis Biotherapeutics, Amicus Therapeutics, and ANI Pharmaceuticals are highlighted for their potential to outperform. The industry's outlook appears bright despite challenges, with a focus on innovation, strategic collaborations, and expanding portfolios.

Arcutis Biotherapeutics (NASDAQ:ARQT) insider Patrick Burnett sold 11,500 shares of the company's stock on December 15th at an average price of $28.94, totaling $332,810. This sale decreased his position by 10.47% to 98,307 shares, continuing a trend of recent disposals. The company's stock is currently trading around $28.34, with a market capitalization of $3.47 billion, and analysts generally rate it a "Moderate Buy" with an average price target near $29.00.